文献速递心律失常

种族/民族与房颤患者口服抗凝药使用的关联:ORBIT-AF II 注册研究

Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II.
PubMed 文献 · JAMA Cardiol · 2018-01-01

基于美国 ORBIT-AF II 前瞻性注册研究(2013 年 2 月至 2016 年 7 月,12 417 例非短暂性房颤门诊患者),分析白人、黑人和西班牙裔患者口服抗凝药(尤其 DOAC)使用的差异。调整临床特征后,黑人患者接受任何口服抗凝药(aOR 0.75,95%CI 0.56-0.99)及 DOAC(aOR 0.63,95%CI 0.49-0.83)的几率均低于白人;进一步控制社会经济因素后,任何口服抗凝药差异不再显著(aOR 0.78,95%CI 0.59-1.04),但 DOAC 使用仍较低(aOR 0.73,95%CI 0.55-0.95)。西班牙裔与白人无显著差异,但黑人和西班牙裔使用华法林时治疗目标范围内时间更低,DOAC 不适当剂量更常见。

要点

  • 调整临床特征后,黑人房颤患者接受任何口服抗凝药和 DOAC 的几率均低于白人。
  • 进一步控制社会经济因素后,黑人患者 DOAC 使用仍显著低于白人(aOR 0.73)。
  • 黑人和西班牙裔使用华法林时 TTR 更低,DOAC 不适当剂量更常见。

核心结论

  • 控制临床和社会经济因素后,黑人房颤患者接受 DOAC 的几率仍低于白人,西班牙裔与白人无差异。
  • 接受抗凝治疗的黑人和西班牙裔患者抗凝质量低于白人。

研究设计与样本

  • 基于美国 ORBIT-AF II 前瞻性注册研究,纳入 2013 年 2 月至 2016 年 7 月随访的 21 岁以上非短暂性房颤门诊患者,共 12 417 例。
  • 按自我报告的种族/民族分为白人(11 100 例,88.6%)、黑人(646 例,5.2%)和西班牙裔(671 例,5.4%)。
  • 主要结局为使用任何口服抗凝药,尤其 DOAC;次要结局包括抗凝质量和 1 年口服抗凝药停药。

主要发现

  • 调整临床特征后,黑人患者接受任何口服抗凝药的几率低于白人(aOR 0.75,95%CI 0.56-0.99),接受 DOAC 的几率也低于白人(aOR 0.63,95%CI 0.49-0.83)。
  • 进一步控制社会经济因素后,黑人患者接受任何口服抗凝药的差异不再显著(aOR 0.78,95%CI 0.59-1.04),但 DOAC 使用仍显著较低(aOR 0.73,95%CI 0.55-0.95)。
  • 西班牙裔与白人之间口服抗凝药使用无显著差异。
  • 接受华法林的患者中,黑人 TTR 中位数 57.1%(IQR 39.9%-72.5%),西班牙裔 51.7%(IQR 39.1%-66.7%),均低于白人 67.1%(IQR 51.8%-80.6%)(P < .001)。
  • 接受 DOAC 的患者中,不适当剂量在黑人和西班牙裔中更常见:黑人 61/394(15.5%),西班牙裔 74/409(18.1%),白人 1003/7988(12.6%)(P = .01)。

临床怎么用

  • 对黑人房颤患者应关注 DOAC 处方不足及不适当剂量问题,优化抗凝治疗。
  • 对黑人和西班牙裔使用华法林者需加强 INR 管理以提高 TTR。
  • 识别可改变差异原因可能改善房颤治疗质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Black and Hispanic patients are less likely than white patients to use oral anticoagulants for atrial fibrillation. Little is known about racial/ethnic differences in use of direct-acting oral anticoagulants (DOACs) for atrial fibrillation. OBJECTIVE: To assess racial/ethnic differences in the use of oral anticoagulants, particularly DOACs, in patients with atrial fibrillation. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II, a prospective, US-based registry of outpatients with nontransient atrial fibrillation 21 years and older who were followed up from February 2013 to July 2016. Data were analyzed from February 2017 to February 2018. EXPOSURES: Self-reported race/ethnicity as white, black, or Hispanic. MAIN OUTCOMES AND MEASURES: The primary outcome was use of any oral anticoagulant, particularly DOACs. Secondary outcomes included the quality of anticoagulation received and oral anticoagulant discontinuation at 1 year. RESULTS: Of 12 417 patients, 11 100 were white individuals (88.6%), 646 were black individuals (5.2%), and 671 were Hispanic individuals (5.4%) with atrial fibrillation. After adjusting for clinical features, black individuals were less likely to receive any oral anticoagulant than white individuals (adjusted odds ratio [aOR], 0.75 [95% CI, 0.56, 0.99]) and less likely to receive DOACs if an anticoagulant was prescribed (aOR, 0.63 [95% CI, 0.49-0.83]). After further controlling for socioeconomic factors, oral anticoagulant use was no longer significantly different in black individuals (aOR, 0.78 [95% CI, 0.59-1.04]); among patients using oral anticoagulants, DOAC use remained significantly lower in black individuals (aOR, 0.73 [95% CI, 0.55-0.95]). There was no significant difference between white and Hispanic groups in use of oral anticoagulants. Among patients receiving warfarin, the median time in therapeutic range was lower in black individuals (57.1% [IQR, 39.9%-72.5%]) and Hispanic individuals (51.7% [interquartile range {IQR}, 39.1%-66.7%]) than white individuals (67.1% [IQR, 51.8%-80.6%]; P < .001). Black and Hispanic individuals treated with DOACs were more likely to receive inappropriate dosing than white individuals (black patients, 61 of 394 [15.5%]; Hispanic patients, 74 of 409 [18.1%]; white patients, 1003 of 7988 [12.6%]; P = .01). One-year persistence on oral anticoagulants was the same across groups. CONCLUSIONS AND RELEVANCE: After controlling for clinical and socioeconomic factors, black individuals were less likely than white individuals to receive DOACs for atrial fibrillation, with no difference between white and Hispanic groups. When atrial fibrillation was treated, the quality of anticoagulant use was lower in black and Hispanic individuals. Identifying modifiable causes of these disparities could improve the quality of care in atrial fibrillation.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Essien UR, Holmes DN, Jackson LR, et al. Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. JAMA Cardiol. 2018. PMID: 30484833. doi:10.1001/jamacardio.2018.3945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。